14 recruiting, 8 not yet recruiting, 6 enrolling by invitation, 4 active not recruiting. 3 Not applicable, 3 Phase 2, 2 Phase 4, 1 Phase 1, 1 Phase 3.
Follow Hypertrophic Cardiomyopathy (HCM): new trials by email Literature Review of Hypertrophic Cardiomyopathy (HCM) trials Research Report on Hypertrophic Cardiomyopathy (HCM)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aficamten and Patient-Reported Outcomes in Real-World nHCM receiving aficamten - Hypertrophic Cardiomyopathy (HCM) | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2027-06-01 | 2026-09-29 | |
| Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy QG101-23-0 enteric coated capsule (60/120/240/360 mg BID), QG101-23-0 enteric coated capsule (120/240/360/480mg BID) - Hypertrophic Cardiomyopathy (HCM), Obstructive HCM (oHCM) | Phase 2 | Not yet recruiting | Amckaus PTY LTD. | 56 | 2026-10-01 | 2026-06-30 |
| Individualized Exercise Training in Hypertrophic Cardiomyopathy Exercise Intervention, Physical Activity Handout - Hypertrophic Cardiomyopathy (HCM) | Not applicable | Not yet recruiting | Oregon Health and Science University | 60 | 2026-09-15 | 2026-09-23 |
| HCMR Re-Imaging Study None - observational study - Hypertrophic Cardiomyopathy (HCM) | Recruiting | Christopher Kramer | 314 | 2026-07-27 | 2026-10-16 | |
| A Real-world HCM-cohort Trial Standard of care - Hypertrophic Cardiomyopathy (HCM) | Not yet recruiting | Xijing Hospital | 3000 | 2026-06-30 | 2026-06-10 | |
| A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population No interventions were applied to the patients. - Hypertrophic Cardiomyopathy (HCM) | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 3000 | 2026-06-01 | 2026-09-15 | |
| Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy Observational study, no new intervention offered - Hypertrophic Cardiomyopathy (HCM) | Not yet recruiting | University of Manchester | 140 | 2026-06-01 | 2026-02-13 | |
| Radiomics Analysis of CMR Imaging for Arrhythmic Risk Prediction in Hypertrophic Cardiomyopathy, With Longitudinal Risk Reassessment After Mavacamten Therapy in Obstructive Patients Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitors | Active not recruiting | Centro Cardiologico Monzino | 2000 | 2026-06-01 | 2026-07-10 | |
| Mechanisms of Atrial Pathoelectrophysiology in HCM Hypertrophic Cardiomyopathy (HCM), Atrial Fibrillation (AF) | Recruiting | Guy's and St Thomas' NHS Foundation Trust | 40 | 2026-05-26 | 2026-09-11 | |
| Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy Aficamten - Hypertrophic Cardiomyopathy (HCM) | Phase 4 | Recruiting | Oregon Health and Science University | 40 | 2026-05-05 | 2026-05-20 |
| Myocardial Energetic Restoration in the Treatment of Obstructive Hypertrophic Cardiomyopathy Hypertrophic Cardiomyopathy (HCM) | Not yet recruiting | University of Manchester | 20 | 2026-04-30 | 2026-01-12 | |
| Multicentre Hypertrophic Cardiomyopathy Registry Hypertrophic Cardiomyopathy (HCM) | Recruiting | University of Manchester | 2500 | 2026-04-01 | 2026-05-01 | |
| The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction mavacamten, Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol, diltiazem - Hypertrophic Cardiomyopathy (HCM) | Phase 4 | Enrolling by invitation | Second Affiliated Hospital, Zhejiang University, School of Medicine | 132 | 2026-03-01 | 2026-09-15 |
| LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain. Anticoagulant treatment Rivaroxaban, Best medical therapy - Hypertrophic Cardiomyopathy (HCM) | Phase 3 | Recruiting | Rennes University Hospital | 532 | 2026-01-07 | 2026-06-12 |
| Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases Injection of 68Ga-NI-FAPI - Tumor, Cardiovascular Diseases | Phase 1 / Phase 2 | Recruiting | Peking Union Medical College Hospital | 30 | 2025-12-17 | 2026-03-11 |
| Multimodal Analysis of Endomyocardial Biopsies Heart Transplantation, Dilated Cardiomyopathy (DCM) | Recruiting | University Hospital, Essen | 216 | 2025-10-27 | 2026-01-22 | |
| ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access Hypertrophic Cardiomyopathy (HCM), Cardiac Imaging | Terminated | UltraSight | 36 | 2025-07-25 | 2026-03-09 | |
| Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM) Retrospective data collection - Hypertrophic Cardiomyopathy (HCM), Heart Failure | Recruiting | Deutsches Herzzentrum Muenchen | 100 | 2025-06-17 | 2026-02-18 | |
| Role of Cardiovascular Imaging in the Early Diagnosis of Hypertrophic Cardiomyopathy in Women Hypertrophic Cardiomyopathy (HCM) | Active not recruiting | IRCCS San Raffaele | 80 | 2025-03-01 | 2025-03-18 | |
| Early Identification and Treatment of Rare Cardiomyopathy Cohorts diuretics, ACEIs/ARBs, beta blockers, positive inotropic drugs, MRAs, SGLT2i, retinoids, Close follow-up, early rehabilitation guidance - Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM) | Not applicable | Not yet recruiting | RenJi Hospital | 300 | 2025-02-01 | 2025-01-27 |
Showing 20 of 37. Sign in to see all of them.
Cardiomyopathy, Hypertrophic (37) · Cardiomyopathy, Dilated (7) · Amyloid Neuropathies, Familial (4) · Arrhythmogenic Right Ventricular Dysplasia (4) · Cardiomyopathies (4) · Myocarditis (4) · Cardiomyopathy, Restrictive (3) · Death, Sudden, Cardiac (3) · Cardiovascular Diseases (2) · Disease (2) · Fabry Disease (2) · Heart Failure (2) · Long QT Syndrome (2) · Myotonic Dystrophy (2) · Polymorphic Catecholaminergic Ventricular Tachycardia (2)
Aortic Stenosis, Subvalvular (37) · Aortic Valve Disease (37) · Aortic Valve Stenosis (37) · Heart Diseases (37) · Heart Valve Diseases (37) · Cardiovascular Diseases (35) · Cardiomyopathies (33) · Pathological Conditions, Signs and Symptoms (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Pathologic Processes (10) · Cardiomegaly (8) · Genetic Diseases, Inborn (8) · Laminopathies (6) · Nervous System Diseases (6) · Heredodegenerative Disorders, Nervous System (5)
MYK-461 (3) · Adrenergic beta-Antagonists (2) · BID protein, human (1) · Bisoprolol (1) · Carvedilol (1) · Diltiazem (1) · Diuretics (1) · Drug Therapy (1) · Equipment and Supplies (1) · Large Language Models (1) · MRAS protein, human (1) · Magnetic Resonance Imaging (1) · Metoprolol (1) · Observation (1) · Retinoids (1)
Second Affiliated Hospital, Zhejiang University, School of Medicine (4) · University of Manchester (3) · Chinese Academy of Medical Sciences, Fuwai Hospital (2) · Oregon Health and Science University (2) · Amckaus PTY LTD. (1) · Bristol-Myers Squibb (1) · Central State Medical Academy (1) · Centro Cardiologico Monzino (1) · Christopher Kramer (1) · Cytokinetics (1) · Deutsches Herzzentrum Muenchen (1) · Guy's and St Thomas' NHS Foundation Trust (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · IRCCS San Raffaele (1) · Johns Hopkins University (1)
China (9) · United States (9) · Italy (5) · United Kingdom (4) · France (2) · Germany (2) · Canada (1) · Netherlands (1) · Russia (1) · Spain (1)
Andreas Barth, MD (1) · Chenguang Li, MD, PhD (1) · Christopher Kramer, MD (1) · Donal Erwan (1) · Elena Biagini, MD, PhD (1) · Euan A Ashley, BSc, MB ChB, DPhil (1) · Gianluca Pontone, MD (1) · Lars Michel, PD Dr. med. (1) · Ling Tao, MD, Ph.D (1) · Meng Jiang, MD, PhD (1) · Milind Desai, MD. (1) · Paolo Della Bella, MD (1) · Stefan Neubauer, MD (1)
PMID 25657602, PMID 34081217, PMID 38493832, PMID 41212168
2019 (1), R01HL128743 (1)